2022 American Transplant Congress
COVID-19 Syndrome After Liver Transplant: Immunosuppression Role and Risk Factors for Mortality
*Purpose: Data on mortality and immunosuppression role regarding Liver transplant recipients affected by COVID-19 are still under debate. The present study identified risk factors for…2022 American Transplant Congress
Disruption of B Cell Population is Associated with Increased Infections in Pediatric Transplant Recipients
Pediatrics, UCSD Rady Children's, San Diego, CA
*Purpose: Solid-organ transplant recipients are placed on long-term immunosuppression, preventing graft rejection but increasing the risk of infection. Pediatric transplant recipients are at increased risk…2022 American Transplant Congress
Accepting Rejection in Liver Transplant Recipients Requiring Renal Replacement Therapy: A Practice Paradigm
*Purpose: The purpose of this study is to evaluate rejection outcomes in those requiring renal replacement therapy (RRT) after liver transplant.*Methods: This was a single…2022 American Transplant Congress
The Application of Activated Stem Cells from Human Exfoliated Deciduous Teeth (SHED) in Islet Transplantation for Novel Immunosuppressive Therapy
*Purpose: While various attempts have been made to improve the efficiency of islet transplantation, we have been working on the analysis of the mechanism of…2022 American Transplant Congress
Chimeric Antigen Receptor Regulatory T Cells (CAR-Tregs) Provide Significantly Greater Modulation of Alloimmune Responses Than Alternative Alloantigen-Specific Treg Strategies
1King's College London, London, United Kingdom, 2Quell Therapeutics, London, United Kingdom
*Purpose: Conferring alloantigen-specificity to ex vivo expanded CD4+CD25+Foxp3+ Tregs increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. This has…2022 American Transplant Congress
Defining the Longitudinal Dynamics of Immune Cells in Blood in the First Year After Pediatric Liver Transplantation (pLTx)
*Purpose: In the European multicentre “ChilSFree” study we aimed for a deep characterisation of the longitudinal immune dynamics during the first year after pLTx.*Methods: Absolute…2022 American Transplant Congress
Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial
*Purpose: Ixazomib is a second-generation oral proteasome inhibitor, FDA approved for the treatment of refractory multiple myeloma. The purpose of the study was (1) to…2022 American Transplant Congress
Variable Course of Hepatitis A Virus Infection in Solid Organ Transplant Recipients
*Purpose: Although Hepatitis A virus (HAV) infection is typically a self-limited disease in immunocompetent individuals, the natural history and viral kinetics of HAV in solid…2022 American Transplant Congress
Humoral and Cellular Immunity 6 Months After SARS-CoV-2 Infection in Solid-Organ Transplant Recipients
*Purpose: The purpose of this study was to evaluate long term humoral and cellular immunity generated following SARS-CoV-2 infection in solid organ transplant recipients (SOTR).*Methods:…2022 American Transplant Congress
Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients
*Purpose: Previous twice-a-day tacrolimus formulations available were capsular and of limited dose formulations (0.5mg, 1mg). Recently a new tablet formulation of tacrolimus with more diverse…